Boston Scientific to acquire Penumbra in $14.5 billion deal
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Subscribe To Our Newsletter & Stay Updated